Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Published Online
on November 2, 2009

Circulation. 2009
Published online before print November 2, 2009, doi: 10.1161/CIRCULATIONAHA.109.855817
A more recent version of this article appeared on November 17, 2009
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
120/20/1943    most recent
CIRCULATIONAHA.109.855817v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Franco, O. H.
Right arrow Articles by D'Agostino, R. B.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Franco, O. H.
Right arrow Articles by D'Agostino, R. B., Sr
Related Collections
Right arrow Primary prevention
Right arrow Chronic ischemic heart disease
Right arrow Epidemiology
Right arrowRelated Article

Submitted on February 2, 2009
Accepted on September 4, 2009

Trajectories of Entering the Metabolic Syndrome. The Framingham Heart Study

Oscar H. Franco MD, DSc, PhD*, Joseph M. Massaro PhD, Jacky Civil PhD, Mark R. Cobain PhD, Brendan O'Malley PhD, and Ralph B. D'Agostino Sr PhD

From Unilever Corporate Research, Sharnbrook, UK (O.H.F., J.C., M.R.C., B.O.); University of Warwick, Warwick Medical School, Health Sciences Research Institute, Coventry, UK (O.H.F.); Department of Mathematics/Statistics and Biostatistics, Boston University, Boston, Mass (J.M.M.); and the National, Heart, Lung and Blood Institute's Framingham Heart Study, Framingham, Mass (R.B.D.).

* To whom correspondence should be addressed. E-mail: O.H.Franco{at}warwick.ac.uk.

Background—We evaluated the progression of the metabolic syndrome (MetS) and its components, the trajectories followed by individuals entering MetS, and the manner in which different trajectories predict cardiovascular disease and mortality.

Methods and Results—Using data from 3078 participants from the Framingham Offspring Study (a cohort study) who attended examinations 4 (1987), 5 (1991), and 6 (1995), we evaluated the progression of MetS and its components. MetS was defined according to the Adult Treatment Panel III criteria. Using logistic regression, we evaluated the predictive ability of the presence of each component of the MetS on the subsequent development of MetS. Additionally, we examined the probability of developing cardiovascular disease or mortality (until 2007) by having specific combinations of 3 that diagnose MetS. The prevalence of MetS almost doubled in 10 years of follow-up. Hyperglycemia and central obesity experienced the highest increase. High blood pressure was most frequently present when a diagnosis of MetS occurred (77.3%), and the presence of central obesity conferred the highest risk of developing MetS (odds ratio, 4.75; 95% confidence interval, 3.78 to 5.98). Participants who entered the MetS having a combination of central obesity, high blood pressure, and hyperglycemia had a 2.36-fold (hazard ratio, 2.36; 95% confidence interval, 1.54 to 3.61) increase of incident cardiovascular events and a 3-fold (hazard ratio, 3.09, 95% confidence interval, 1.93 to 4.94) increased risk of mortality.

Conclusions—Particular trajectories and combinations of factors on entering the MetS confer higher risks of incident cardiovascular disease and mortality in the general population and among those with MetS. Intense efforts are required to identify populations with these particular combinations and to provide them with adequate treatment at early stages of disease.


Key words: cardiovascular diseases • Framingham study • metabolic syndrome • prevention • syndrome X


Related Article:

Clinical Summaries
Circulation 2009 120: 1935-1936. [Extract] [Full Text]